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Abstract
Background: The prognosis for patients with advanced epithelial ovarian cancer remains poor despite
aggressive surgical resection and platinum-based chemotherapy. More than 60% of patients will develop
recurrent disease, principally intraperitoneal, and die within 5 years. The use of whole abdominal
irradiation (WAI) as consolidation therapy would appear to be a logical strategy given its ability to sterilize
small tumour volumes. Despite the clinically proven efficacy of whole abdominal irradiation, the use of
radiotherapy in ovarian cancer has profoundly decreased mainly due to high treatment-related toxicity.
Modern intensity-modulated radiation therapy (IMRT) could allow to spare kidneys, liver, and bone
marrow while still adequately covering the peritoneal cavity with a homogenous dose.
Methods/Design: The OVAR-IMRT-01 study is a single center pilot trial of a phase I/II study. Patients
with advanced ovarian cancer stage FIGO III (R1 or R2< 1 cm) after surgical resection and platinum-based
chemotherapy will be treated with whole abdomen irradiation as consolidation therapy using intensity
modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions. A total of 8 patients will
be included in this trial. For treatment planning bone marrow, kidneys, liver, spinal cord, vertebral bodies
and pelvic bones are defined as organs at risk. The planning target volume includes the entire peritoneal
cavity plus pelvic and para-aortic node regions.
Discussion: The primary endpoint of the study is the evaluation of the feasibility of intensity-modulated
WAI and the evaluation of the study protocol. Secondary endpoint is evaluation of the toxicity of intensity
modulated WAI before continuing with the phase I/II study. The aim is to explore the potential of IMRT
as a new method for WAI to decrease the dose to kidneys, liver, bone marrow while covering the
peritoneal cavity with a homogenous dose, and to implement whole abdominal intensity-modulated
radiotherapy into the adjuvant multimodal treatment concept of advanced ovarian cancer FIGO stage III.
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Background
Ovarian cancer remains the number one gynaecological
killer in the western world [1]. Symptoms tend to be
vague; hence ovarian cancer is often detected late [2,3].
Approximately 70% of ovarian cancer patients present
with advanced stage disease after it has spread beyond the
genital organs and into the peritoneal cavity (stage FIGO
III) or even further (stage FIGO IV, distant metastases).
With a 5-year survival about 70% of patients with ovarian
cancer stage II, the overall survival dramatically decreases
in the advanced stages of disease, in stage III and IV it is
only about 31% and 13% respectively [4,5].
The standard management of ovarian carcinoma is aggres-
sive surgical resection (including at least total abdominal
hysterectomy, bilateral adnexectomy, omentectomy,
debulking of tumour masses) followed by platinum-
based adjuvant chemotherapy. Generally this includes 6
courses of carboplatin or cisplatin (AUC 5) IV and paclit-
axel (175 mg/m2) IV, every 3 weeks [6-11]. While the
majority of patients respond to treatment, most will
relapse, principally intraperitoneal, resulting in 5-year sur-
vival rates for advanced disease of approximately 20–25%
[12,13].
However, subgroups of patients profiting from an even
more aggressive treatment can be identified according to
prognostic criteria such as stage, residual disease and grad-
ing. Patients with FIGO stage III G2/G3 with residual dis-
ease < 2 cm and FIGO stage II G3 R<2 cm are classified as
high risk, with a risk of recurrence of around 80% with a
5-year survival of 25 % [14]. Hence, this subgroup of
patients needs further efforts to improve outcome.
By now, several sometimes randomized trials have evalu-
ated strategies of consolidation therapy for high risk
patients (continuation of chemotherapy, other chemo-
therapy, high-dose chemotherapy followed by stem cell
transplant, intraperitoneal chemotherapy, unspecific
immunotherapy) but were not able to improve outcome
significantly so far [5,9,10,15-17].
The use of whole abdominal irradiation (WAI) as a con-
solidation therapy would appear to be a logical strategy.
The fact that whole abdominal radiotherapy can be cura-
tive in certain groups of patients has been shown by inten-
sive studies by Dembo et al [18,19]. During the 1950s
surgery and radiotherapy were the predominant treatment
modalities in ovarian cancer. However, with the introduc-
tion of chemotherapy during the late 1950s and its proven
effects in advanced ovarian cancer (yielding the best pri-
mary response rate), radiotherapy has been more and
more abandoned mostly due to marked side effects [20].
Typically, a dose of 30 Gy is given to the whole abdomen
with an anterior-posterior/posterior-anterior beam
arrangement and posterior shielding of the kidneys [21].
Due to the extensive field sizes (40 cm × 30 cm or larger),
a high percentage of patients experienced severe side
effects, myelosuppression being the most commonly
reported. Moreover, the shielding of organs at risk delivers
inadequate low doses in parts of the target volume thus
reducing efficiency of radiation [22-25].
Postoperative radiotherapy as a consolidation treatment
with or without prior chemotherapy been investigated on
numerous occasions, though initially with inconsistent
and often disappointing results [26,27]. Thomas reviewed
whole-abdominal pelvic irradiation in 28 published trials
prior to 1992 [28,29]. Even though 700 patients were
treated overall in these trials, it was impossible to reach a
definitive conclusion as to the role of whole-abdominal
irradiation for consolidation because of the diversity of
criteria for patient selection, and the variability in the
chemotherapy, surgery and radiation technique. Thomas
gave some possible causes for these disappointing results
in order to guide the design for future studies, the first
being inappropriate patient selection based on large-vol-
ume residuum. Some authors suggest the initial residuum
prior to chemotherapy should be less than 2 cm [26].
Most authors believe that radiotherapy should follow sur-
gery and chemotherapy in case of small residual tumours
(< 5 mm) or only microscopically detectable rests [30].
In addition to inappropriate patient selection, another
possible explanation for the treatment failure observed in
these trials is the high-degree of toxicity resulting in
delayed or incomplete radiotherapy. Cumulative bone
marrow toxicity is also increased in patients receiving
additional chemotherapy. Inability to complete sequen-
tial therapy as planned in a significant proportion of
patients may be a contributing factor to the lack of overall
benefit [20,25,29]. Thus, if sequential multimodality ther-
apy is to be tested, it is important to keep the risk of com-
plications to a minimum maximising the probability of
completing radiotherapy successfully. Severe late intesti-
nal radiation reactions were recorded in about 10% [28].
These were associated with additional pelvic boost and
previous second-look laparotomy, which is nowadays
obsolete.
Recent studies have shown more promising findings.
1999 a retrospective case control study compared the out-
come of patients with advanced ovarian cancer after sur-
gery followed by chemotherapy with the combination of
surgery, chemotherapy and irradiation. The results
showed a significantly improved disease-free survival for
patients in the radiotherapy group, and suggested that the
role of radiotherapy should be re-evaluated in a prospec-
tive randomized study [30].BMC Cancer 2007, 7:227 http://www.biomedcentral.com/1471-2407/7/227
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Also in 1999, results from 64 patients with advanced ovar-
ian cancer without residual disease after surgery and car-
boplatin-based chemotherapy were randomized to either
chemotherapy alone or chemotherapy plus consolidation
radiotherapy. There was a significantly prolonged relapse-
free interval and the overall survival in the radiotherapy
arm in this study with differences being more pronounced
in patients with FIGO stage III [31].
2003 a randomized trial compared whole abdominal
radiation therapy, chemotherapy and no further treat-
ment in advanced ovarian cancer (FIGO III). One hun-
dred seventy-two patients achieved a complete surgical
remission after induction chemotherapy. In the subgroup
with complete pathologic remission, progression-free sur-
vival was significantly better in patients treated with radi-
otherapy (56% at 5 years) than with chemotherapy alone
(36% at 5 years), and the untreated control group (35% at
5 years). Overall survival was also most favourable in the
radiotherapy group (69% at 5 years), however, this differ-
ence failed to achieve statistical significance (P = 0,084).
The number of recurrences was also lowest in the radio-
therapy group. In the subgroup with microscopic residual
disease, there was no significant difference in survival
between the radiotherapy and chemotherapy group [32].
One trial published in 2005 aimed to determine the out-
come associated with the use of whole abdominal radio-
therapy in women with ovarian cancer, even after positive
second-look laparotomy (SLL) or second look debulking
for recurrent disease. The investigators came to the conclu-
sion that radiotherapy appeared to be an efficacious treat-
ment option for patients with microscopic disease at SLL,
but does not appear to be more effective than chemother-
apy in patients with macroscopic disease at SLL [33].
2003 a swedish systematic review of radiation therapy tri-
als came to the conclusion there might be some evidence
to suggest that radiotherapy plays a role as consolidation
therapy in patients with advanced ovarian cancer and
pathologically complete response after chemotherapy
[34].
In summary, the review of available literature demon-
strates a rationale in favour of consolidation whole
abdominal irradiation in advanced ovarian cancer. Whole
abdominal irradiation after surgical resection and plati-
num-based adjuvant chemotherapy seems to increase dis-
ease-free and overall survival in patients with ovarian
cancer disease stage FIGO III with no or only minimal
residual disease. However, classical WAI technique after
surgery and chemotherapy is associated with high toxici-
ties, particularly haematological toxicity, which leads to
treatment interruptions.
Technical developments in radiotherapy techniques like
intensity-modulated radiation therapy (IMRT) have now
the potential to spare organs at risk (OARs) as kidneys,
liver, and bone marrow [35,36]. Hence, these techniques
might significantly decrease the toxicity while still ade-
quately covering the peritoneal cavity with a homogenous
dose [37]. Intensity-modulated radiation therapy (IMRT)
is a relatively new but increasingly accepted technology
delivering radiation more precisely to the tumour while
sparing surrounding normal tissue [18,19,21,22,38-40].
Treatment planning and delivery with IMRT are a stand-
ard treatment technique now used for sites such as pros-
tate, paraspinal tumours, tumours of the brain, and
head&neck tumours. This technique is also increasingly
explored for more challenging sites like gastro-intestinal
tumours or breast cancer [35,41-48]. The challenge of this
study is the application of this technique to a large and
complexly shaped target volume like the peritoneal cavity
[49,50].
Previous work by our group included inversely planned
IMRT-treatments as a plan comparison based on CT-scans
obtained from an abdominal staging CT scan of a patient
with advanced ovarian cancer after receiving her informed
consent. It could be shown that, in principle, IMRT of the
whole peritoneal cavity is possible, though patient immo-
bilisation using a vacuum mattress and a scotch cast mask
was needed to obtain the required accuracy necessary in
body stereotaxy.
Methods/Design
Study design
The study is designed as a single center pilot trial of a
phase I/II study evaluating the feasibility and toxicity of
intensity-modulated WAI.
Study objectives
The primary objective is to evaluate the feasibility of plan-
ning and treatment application of intensity modulated
whole abdominal irradiation and to evaluate the study
protocol. Secondary endpoint is evaluation of the toxicity
in intensity-modulated whole abdominal irradiation
before the initiation of a prospective phase I/II study.
Trial organisation
OVAR-IMRT-01 has been designed by the study initiators
at the Department of Radiation Oncology at the Univer-
sity of Heidelberg. The trial is carried out by the Depart-
ment of Radiation Oncology at the University of
Heidelberg in co-operation with the German Cancer
Research Center (dkfz) and Department of Gynaecology
and Obstetrics.BMC Cancer 2007, 7:227 http://www.biomedcentral.com/1471-2407/7/227
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Coordination
The overall coordination is performed by the Department
of Radiation Oncology at the University of Heidelberg.
This department is also responsible for the overall trial
management, database management, quality assurance
including monitoring and reporting.
Investigators
The study investigators are experienced radiation oncolo-
gists specialized in the treatment of patients with gynaeco-
logical malignancies. Patients will be recruited and treated
by the physicians of the Department of Radiation Oncol-
ogy of the University of Heidelberg.
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the University of Heidelberg, Heidelberg, Germany
(Nr: 176/2005) and by an independent expert group of
the German Society for Radio-oncology (DEGRO). This
study complies with the Helsinki Declaration in its recent
German version, the Medical Association code of conduct,
the principles of Good Clinical Practice (GCP) and the
Federal Data Protection Act. The trial will also be carried
out in keeping with local legal and regulatory require-
ments. The medical secrecy and the Federal Data Protec-
tion Act will be followed. The ClinicalTrials.gov Protocol
ID is NCT00527631.
Patient selection
Inclusion criteria into the study protocol are:
- histologically confirmed ovarian cancer stage FIGO III
- grade 2 or 3
- maximal typical surgical resection (including at least
total abdominal hysterectomy, bilateral adnexectomy,
omentectomy, debulking of tumour masses)
- postoperative residual tumour of less than 1 cm (maxi-
mal diameter of largest tumour residual is 1 cm)
- adjuvant chemotherapy consisting of six courses of car-
boplatin/paclitaxel or carboplatin/docetaxel
- mplete remission after chemotherapy
- Karnofsky performance Score >60
- patients > 18 and < 75 years of age
- written informed consent
Exclusion criteria
- stage FIGO I or II
- stage IV (distal metastasis) stage
- III R2 > 1 cm
- delayed wound healing post laparotomy
- obesity
- neutrophil count (ANC) < 2000/ml before radiotherapy
- platelets < 100000/ml
- connective tissue disease, sclerodermia
- clinically active renal, hepatic, cardiac, metabolic, respi-
ratory, coagulation or haematopoietic disease
- participation in another clinical trial
- patient refusal
Statistical calculations for trial sample size
The primary objective is to evaluate the feasibility of plan-
ning and application of intensity-modulated whole
abdominal irradiation. 8 patients will be included into
the study. If planning and treatment application is not fea-
sible for the first 5 patients the study will be discontinued.
Adverse events
Radiotherapy-related toxicities will be assessed using the
NCI Common Toxicity Criteria (CTC). Toxicity will be
evaluated pre-treatment, weekly during radiation therapy
(blood count, electrolytes, chemistry, clinical examina-
tion, patient visits) and at follow-up. Unacceptable toxic-
ity is defined as unpredictable or irreversible grade 4
toxicity.
Expectable possible acute toxicities (up to 3 months post
radiation therapy) are fatigue, loss of appetite, weight loss,
skin toxicity (epitheliolysis, erythema, hyperpigmenta-
tion), nausea, vomiting, irritable bowel syndrome,
diarrhea, intestinal bleeding, proctitis, dysuria, interstitial
nephritis, hepatitis, pneumonitis, haematological toxicity
with thrombocytopenia, leukocytopenia, anaemia. These
symptoms can be medically treated and usually resolve
within 2–3 weeks. However, transient parenteral nutrition
and hydratation might be necessary in some cases. All
acute toxicities should completely resolve within a few
weeks after radiation therapy.
Late side effects are rare and are defined as symptoms
appearing at least 3 months post radiation. These could
include chronic diarrhea, malabsorbtive syndrome,
chronic bladder inflammation, enterecolitis, strictures,
fibroses, ulcers, chronic bleeding. Very rare symptoms areBMC Cancer 2007, 7:227 http://www.biomedcentral.com/1471-2407/7/227
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fistulation, perforation, peritonitis, intestinal necrosis,
ileus necessitating surgical intervention resulting in intes-
tinal resection/anus praeter formation. In literature
reviews, severe late intestinal radiation reactions were
recorded in about 10%, and were associated with pelvic
boost and previous second-look laparotomy. However,
patients with these risk factors are not included in this
trial. Cardiac, pulmonary, hepatic and renal toxicity with
accompanying renal dysfunction, teleangiectases, and spi-
nal cord toxicities are unlikely with the dose and fraction-
ation applied in the trial.
Radiation therapy
Irradiation is applied as intensity-modulated radiation
therapy (IMRT) using a 6 MeV linear accelerator (Sie-
mens) with a motoric multi-leaf collimator in a step and
shoot technique.
Investigation schedule
Indication
The oncological treatment concept for each patient is
based on interdisciplinary assessment following approved
standard therapies and guidelines. Consent of the col-
leagues from gynaecology, internal medicine and radia-
tion oncology are obligatory. The adjuvant treatment is
defined after surgery and complete staging including
abdominal and transvaginal ultrasound, chest X-ray,
mammography and pelvic-abdominal CT scan if neces-
sary, as well as pre- and post-op tumour marker (CA 125).
This allows for histologically confirmed diagnosis, classi-
fication, and staging. If the patient meets the inclusion cri-
teria chemotherapy is determined and subsequently
indication for irradiation is approved.
Pre-therapeutic examinations
According to the interdisciplinary guidelines for therapy
of ovarian cancer all patients receive 6 cycles of chemo-
therapy followed by a complete staging including pelvic
examination, transvaginal ultrasound, and tumour mark-
ers allowing for assessment of success of the primary ther-
apy. Additionally, abdominal and pelvic CT-scans using
intravenous contrast agent are carried out. Further pre-
irradiation investigations include ECG, blood count, elec-
trolytes, coagulation, as well as blood chemistry.
IMRT treatment-planning
In order to ensure accurate reproducibility of patient posi-
tioning, the patient is immobilized using vacuum mat-
tress and scotch cast head mask (arms over head). CT-
scans are obtained in the immobilisation device and ster-
eotactic body frame in 3 mm-slices. This is done in coop-
eration with the DKFZ according to national DIN norm
and international recommendations (ICRU 50 Report
1999). Target volumes and organs at risk are defined using
the appropriate in-house planning software VIRTUOS
v.4.4.9 for contouring and dose calculation; MRC Konrad
v.1.1.4 is used for optimisation of inversely planned
intensity modulated RT. The target volume includes the
whole peritoneal cavity extending from diaphragm to
douglas cavity. In addition, retroperitoneal, para-aortic
and pelvic nodal areas are included. Kidneys, liver, lungs,
heart and spinal cord, vertebrae, femora, and pelvic bones
are defined as organs at risk (OARs). A dose of 30.0 Gy is
prescribed to median of GTV. No strict constraints are
applied for optimization. In the context of this pilot feasi-
bility trial the goal of optimization is a dose distribution
in the PTV as homogeneous as possible and maximal spar-
ing of organs at risk (OARs) with a high priority on liver,
kidney and bones. Tolerated maximum doses to OARs
must not exceed the TD5/5 for each organ. Time span
allotted for treatment planning is approximately 5 days.
IMRT-treatment
After validation of the treatment plan by the radiation
oncologist and the physicist in charge, treatment is
applied in daily fractions of 5 × 1.5 Gy per week to a total
dose of 30 Gy. Total treatment duration hence is 4 weeks.
Isocenter and patient positioning are checked on the first
fraction and then weekly with the in-room CT (Siemens
Primatom). Treatment times are around 35–45 min.
Treatment will be carried out on an out-patient basis
unless the patient's condition requires hospital admis-
sion.
Follow up
Patients are included into standard gynaecology follow-
up program. This includes follow-up visits at 6 weeks, 3
months, 6 months, 9 months, 12 months, post treatment,
and then every 6 months for 5 years. Each visit includes
pelvic examination, transvaginal ultrasound and tumour
marker checks. In addition, pelvic-abdominal CT-scans
are performed 6, 12, 24, 36 months post treatment.
Monitoring
Monitoring is performed according good clinical practice
(GCP) guidelines. The data management will be per-
formed by the Clinical Trial Center of the Department of
Radiation Oncology, University of Heidelberg.
Discussion
Ovarian cancer remains the number one gynaecological
killer in the western world. Most ovarian cancer patients
present with advanced-stage disease and are treated with
cytoreductive surgery followed by platinum-based combi-
nation chemotherapy. While the majority of patients
respond to treatment, most will relapse, principally intra-
peritoneal, such as the 5-year survival rate for advanced
disease is approximately 20–25%.BMC Cancer 2007, 7:227 http://www.biomedcentral.com/1471-2407/7/227
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The use of whole abdominal irradiation (WAI) as consol-
idation therapy would appear to be a logical strategy given
its ability to sterilize small tumour volumes. During the
1950s surgery and radiotherapy were the predominant
treatment modalities in ovarian cancer. But despite whole
abdominal irradiation's (WAI) clinically proven efficacy
and with the introduction of chemotherapy the use of
radiotherapy in ovarian cancer has profoundly decreased
mainly due to high toxicity. Technical developments in
radiotherapy techniques like intensity-modulated radia-
tion therapy (IMRT) have now the potential to spare
organs at risk (OARs) as kidneys, liver, and bone marrow.
Hence, these techniques might significantly decrease the
toxicity while still adequately covering the peritoneal cav-
ity with a homogenous dose.
The OVAR-IMRT-01 study is a single center pilot trial of a
phase I/II study. After surgical resection and platinum-
based chemotherapy patients with advanced ovarian can-
cer stage FIGO III (R1 or R2< 1 cm) will be treated as con-
solidation therapy with whole abdomen irradiation
(WAI) using intensity modulated radiation therapy
(IMRT) to a total dose of 30 Gy in 1.5 Gy fractions. The
primary endpoint of the study is the evaluation of the fea-
sibility of intensity modulated WAI and study protocol.
Secondary endpoint is evaluation of the toxicity of inten-
sity modulated WAI before initiating a prospective phase
I/II study. The aim is to explore the potential of IMRT as a
new method for WAI to lower the dose to kidneys, liver,
bone marrow while covering the peritoneal cavity with a
homogenous dose, and to implement whole abdominal
intensity modulated radiotherapy into the adjuvant mul-
timodal treatment concept of advanced ovarian cancer
FIGO stage III.
Abbreviations
CTC Common Toxicity Criteria
dkfz German Cancer Research Center
FIGO International Federation of Gynaecology and
Obstetrics
GCP Good Clinical Practice
IMRT Intensity Modulated Radiation Therapy
PTV Planning Target Volume
SLL Second-Look Laparotomy
TD5/5 Tolerance Dose 5% over 5 years
WAI Whole Abdominal Irradiation
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